Two double-blind randomized controlled trials ( RCT ) with Souvenaid of @ and @ week duration ( Souvenir I and Souvenir II ) showed that memory performance was improved in drug-nave mild AD patients , whereas no effects on cognition were observed in a @-week RCT ( S-Connect ) in mild to moderate AD patients using AD medication .